GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on...
Day: February 24, 2023
Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology...
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical...
BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin, 1 January – 31 December 2022 (unaudited)
BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin, 24 February 2023 at 3.00 p.m. BBS advances towards the CE marking of...
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ,...
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving...
Decentralized Trials & Research Alliance Release Best Practices Rubric to Provide Framework to Evaluate DCT Processes
Global cross-industry collaboration continues sharing outputs from portfolio of initiatives SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The Decentralized...
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039WARRINGTON, Pa., Feb. 24, 2023...
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious...
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),...
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y.,...
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
Conference call to be held Tuesday, February 28, 2023 at 8:30 AM ETNEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) --...
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the...
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick...
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its...
Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...
Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023
Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of...
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –...